Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
View Patent ↗The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV). The method includes administering to a cat therapeutically effective amounts of first and second FCV vaccines. The first vaccine is administered orally or parenterally (e.g., subcutaneously, intramuscularly, and the like). The second vaccine is administered orally or oronasally N days following administration of the first vaccine, wherein N is an integer from 3 to 120, inclusive. A third vaccine administration may also be given. The present invention also describes methods and materials for treating and immunizing animals with vaccine, and in particular cats against both FPV or Feline Parvovirus, which has also been called Panleukopenia or FPL and against another disease, FHV or Feline Herpes Virus, which has also been called Feline Rhinotracheitis Virus.
1. A vaccine for immunizing cats against feline calicivirus that comprises FCV-21 capsid protein and a pharmaceutically acceptable carrier, wherein said FCV-21 capsid protein is selected from the group consisting of:
(a) SEQ ID NO:13; and
(b) a polypeptide having at least 95% sequence identity to SEQ ID NO:13.
2. The vaccine of claim 1 , further comprising an adjuvant.
3. The vaccine of claim 1 , wherein said FCV-21 capsid protein is provided in said vaccine as a live, live attenuated, or inactivated FCV-21 virus.
4. The vaccine of claim 1 , further comprising an additional live, attenuated, or inactivated FCV strain, or a component thereof.
5. The vaccine of claim 1 , wherein said FCV-21 capsid protein has at least 99% sequence identify to SEQ ID NO:13.
6. The vaccine of claim 4 , wherein said additional live, attenuated, or inactivated FCV strain, or component thereof, is selected from the group consisting of FCV-F9, FCV-LLK, FCV-M8, FCV-255, and FCV-2280.